Yuhao Wang, Shenghua Cheng, Jueying Chen, Shate Xiang, Rongrong Song, Xiangfeng Shen
Graduated College, Jiangxi University of Chinese Medicine, Nanchang, 330000, Jiangxi, China.
First Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, 310053, Zhejiang, China.
Heliyon. 2024 Jul 2;10(14):e33934. doi: 10.1016/j.heliyon.2024.e33934. eCollection 2024 Jul 30.
Lung cancer remains a formidable global health challenge, necessitating innovative therapeutic strategies for improved efficacy. This review explores the untapped potential of natural products and Traditional Chinese Medicine (TCM) in lung cancer therapy, focusing on targeting ferroptosis regulators. Natural compounds, such as curcumin and resveratrol, exhibit diverse anti-cancer mechanisms, complemented by TCM's holistic approach rooted in a 3500-year history. Emphasizing the induction of cell death, particularly ferroptosis, the review highlights its significance in overcoming challenges like resistance to conventional therapies. Key ferroptosis regulators are explored in the context of natural products and TCM. The impact of these treatments on crucial pathways, such as antioxidant mechanisms (GPX4, SLC7A11, and NRF2), iron metabolism regulators, and lipid and mitochondria pathways, is examined. The findings provide a comprehensive overview of how natural products and TCM modulate ferroptosis in lung cancer, offering valuable insights for the development of innovative, side-effect-reduced therapeutic strategies. This work holds promise for transforming the landscape of lung cancer treatment by integrating the rich resources of nature into conventional therapeutic paradigms.
肺癌仍然是一项严峻的全球健康挑战,需要创新的治疗策略来提高疗效。本综述探讨了天然产物和中药在肺癌治疗中尚未开发的潜力,重点关注靶向铁死亡调节因子。姜黄素和白藜芦醇等天然化合物具有多种抗癌机制,而拥有3500年历史的中医整体疗法也对其起到补充作用。本综述强调诱导细胞死亡,特别是铁死亡,突出了其在克服对传统疗法耐药等挑战方面的重要性。在天然产物和中药的背景下,对关键的铁死亡调节因子进行了探讨。研究了这些治疗方法对关键途径的影响,如抗氧化机制(GPX4、SLC7A11和NRF2)、铁代谢调节因子以及脂质和线粒体途径。这些发现全面概述了天然产物和中药如何调节肺癌中的铁死亡,为开发创新的、副作用更小的治疗策略提供了有价值的见解。通过将丰富的自然资源整合到传统治疗模式中,这项工作有望改变肺癌治疗的局面。
Phytomedicine. 2024-7-25
Front Pharmacol. 2024-5-27
Front Pharmacol. 2024-6-4
Front Pharmacol. 2024-1-16
J Biochem Mol Toxicol. 2025-7
J Inflamm Res. 2025-6-6
Front Pharmacol. 2025-3-21
Signal Transduct Target Ther. 2024-3-8
J Agric Food Chem. 2024-1-17
J Cancer Res Ther. 2023-12-1
Biochem Biophys Res Commun. 2024-1-1
Biomed Pharmacother. 2023-12-31
Front Immunol. 2023
J Biochem Mol Toxicol. 2024-1